DFTX
The table below shows Definium Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $262.52M | $19.96M | $33.39M | $82.85M | $295.28M | $243.13M |
| Short-term investments | $110.90M | $189.11M | $149.60M | $129.59M | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $380.56M |
| $215.85M |
| $189.14M |
| $221.70M |
| $299.36M |
| $247.69M |
| Property, plant & equipment | - | - | - | - | - | - |
| Goodwill | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M |
| Total assets | $401.29M | $236.92M | $265.09M | $275.32M | $319.77M | $268.14M |
| Accounts payable | $7.13M | $8.11M | $4.22M | $2.27M | $2.15M | $2.94M |
| Total current liabilities | $81.11M | $65.42M | $37.96M | $30.48M | $33.27M | $41.85M |
| Long-term debt | $40.77M | $40.38M | $41.19M | $22.04M | $24.31M | $24.25M |
| Total liabilities | $122.44M | $106.32M | $79.69M | $52.52M | $57.58M | $66.10M |
| Retained earnings | -$659.77M | -$532.24M | -$464.97M | -$422.23M | -$364.14M | -$350.45M |
| Total equity | $278.85M | $130.60M | $185.40M | $222.81M | $262.19M | $202.05M |